Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9859623 | 1.00 | MAPT (0.39) | MAPTTAS1R3TAS1R1PPARGHCAR2 | |
| SCHEMBL4939527 | 0.93 | MAPT (0.42) | MAPTPPARGPPARAATM | |
| SCHEMBL4582615 | 0.93 | MAPT (0.42) | MAPTPPARGPPARAATM | |
| SCHEMBL4938624 | 0.93 | MAPT (0.46) | MAPTPPARGALDH1A1PPARAATM | |
| SCHEMBL4582243 | 0.93 | MAPT (0.46) | MAPTPPARGALDH1A1PPARAATM | |
| SCHEMBL4583192 | 0.91 | FAAH (0.44) | MAPTPPARGPPARAATM | |
| SCHEMBL4939335 | 0.91 | FAAH (0.44) | MAPTPPARGPPARAATM | |
| SCHEMBL1883791 | 0.88 | MAPT (0.44) | MAPTPPARGALDH1A1PPARAATM | |
| SCHEMBL10310662 | 0.88 | MAPT (0.44) | MAPTPPARGALDH1A1PPARAATM | |
| SCHEMBL10378199 | 0.88 | MAPT (0.44) | MAPTPPARGALDH1A1PPARAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117945887-A | Preparation method of milbelin intermediate (2E) -4-ethylheptyl-2, 6-dienoic acid | 山东新时代药业有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-9656986-B2 | Compositions comprising TPGS-750-M | MYCELL TECHNOLOGIES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656985-B2 | Surfactant-enabled transition metal-catalyzed chemistry | MYCELL TECHNOLOGIES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170073322-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | MYCELL TECHNOLOGIES, LLC (US) | 2017-03-16 | — | — | US | disclosed |
| US-20160347677-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | MYCELL TECH LLC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160340332-A1 | Compositions Comprising TPGS-750-M | MYCELL TECH LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-8785665-B2 | Surfactant-enabled transition metal-catalyzed chemistry | MYCELL TECHNOLOGIES, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110130562-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | MyCell Holdings Limited | 2011-06-02 | — | — | US | disclosed |
| EP-0425831-A2 | Contact lens | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340332-A1 | Compositions Comprising TPGS-750-M | S100A10, S100A6, TPR | MAPT 1142/4885TAS1R3 1544/4885TAS1R1 1196/4885 |
| US-20170073322-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | SOD1, SMURF1, MUC1 | MAPT 1553/4885TAS1R3 1554/4885TAS1R1 1584/4885 |
| US-20110130562-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | SOD1, SMURF1, MUC1 | MAPT 1553/4885TAS1R3 1554/4885TAS1R1 1584/4885 |
| US-20160347677-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | SOD1, SMURF1, MUC1 | MAPT 1553/4885TAS1R3 1554/4885TAS1R1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.